Showing 232 results

Filters Content type: News, Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

ViiV Healthcare receives approval from China’s national medical products administration for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine)

Editor's pick
ViiV press release
26 October 2023
People with limited treatment options

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Editor's pick
Monthly Prescribing Reference
17 October 2023
Injectable & long-acting HIV treatment

Over 80% With Detectable HIV Load Respond to CAB + RPV LA

Editor's pick
NATAP
17 October 2023
Injectable & long-acting HIV treatment

Treatment Adherence, Persistence in HIV Improves After Switch to Long-Acting ART

Editor's pick
Infectious Disease Advisor
17 October 2023
Pharmaceutical industry

People with HIV offered hope of self-injected drug at home

Editor's pick
The Guardian
3 October 2023
Injectable & long-acting HIV treatment

Could this new hydrogel make HIV therapy more convenient?

Editor's pick
EurekAlert!
28 September 2023
Injectable & long-acting HIV treatment

Long-acting injectable version of the most popular HIV drug combination is possible

News
26 September 2023
Treatment guidelines

Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?

Editor's pick
HIV and ID Observations
25 September 2023
Improving HIV care

Top 5 stories on HIV in Asia from IAS 2023

News
25 August 2023
Injectable & long-acting HIV treatment

Top 5 stories on HIV in Africa from IAS 2023

News
23 August 2023
Injectable & long-acting HIV treatment

Injectable HIV treatment unlikely to be arriving soon in the global south

News
2 August 2023
HIV treatment

Oral lenacapavir can bridge gaps if injections must be missed

News
27 July 2023
The search for a cure

Study demonstrates ability to remove key barrier to an HIV cure

Editor's pick
Medical Xpress
25 July 2023
Injectable & long-acting HIV treatment

The Yin and the Yang of Cabotegravir-Rilpivirine: Part One, the Good News

Editor's pick
HIV and ID Observations
4 July 2023
Injectable & long-acting HIV treatment

Going Long

Editor's pick
POZ
26 June 2023
Injectable & long-acting HIV treatment

Study of Weekly Oral HIV Treatment Resumes

Editor's pick
POZ
8 May 2023
Injectable & long-acting HIV treatment

Why is British Columbia gatekeeping injectable HIV medication?

Editor's pick
Xtra Magazine
4 April 2023
Injectable & long-acting HIV treatment

Clinic finds almost half of people who want long-acting HIV treatment don’t initiate it

Editor's pick
CATIE
30 March 2023
Injectable & long-acting HIV treatment

Thigh injections could be an option for long-acting cabotegravir and rilpivirine

News
22 March 2023
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2023

News
15 March 2023
New & experimental HIV treatments

Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023

News
14 March 2023
HIV treatment

Top 5 HIV treatment stories from CROI 2023

News
13 March 2023
Injectable & long-acting HIV treatment

Rilpivirine resistance may be barrier to long-acting injectable treatment in South Africa

News
7 March 2023
Injectable & long-acting HIV treatment

Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option

News
28 February 2023